You are here

  • Home
  • Online First
  • Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia

Article Text

Article menu

other Versions

Download PDFPDF
Correspondence
Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia
  1. Stephen E Langabeer1,
  2. David O'Brien2,
  3. Sarah McCarron1,
  4. C Larry Bacon2,
  5. Elisabeth Vandenberghe1,2
  1. 1Cancer Molecular Diagnostics, St James's Hospital, Dublin, Ireland
  2. 2Department of Haematology, St James's Hospital, Dublin, Ireland
  1. Correspondence to Dr Stephen E Langabeer, Cancer Molecular Diagnostics, St James's Hospital, Dublin 8, Ireland; slangabeer{at}stjames.ie

https://doi.org/10.1136/jclinpath-2020-207246

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Hairy cell leukaemia (HCL) is a rare, mature, B-cell malignancy characterised clinically by fatigue, splenomegaly, pancytopenia and recurrent opportunistic infections. Morphologically, hairy cells have prominent cytoplasmic projections with classical HCL (HCLc) cells immunophenotypically expressing CD11c, CD19, CD25 and CD103. A variant form (HCLv), that lacks CD25 expression, exhibits a more aggressive clinical course and may not respond to standard HCLc therapies.1 The discovery of the acquired BRAF V600E mutation (c.1799T>A; p.Val600Glu) in nearly all cases of HCLc in 2011, but absent in those patients with HCLv, has added an additional level to the diagnostic algorithm with current guidelines recommending molecular testing for the BRAF V600E in the diagnostic work-up.1–4 In order to establish adherence to guidelines, a retrospective audit was performed on a series of patients with HCL …

    View Full Text

    Footnotes

    • Handling editor Mary Frances McMullin.

    • Contributors SEL, DO and SM performed laboratory studies. CLB and EV provided clinical oversight. All authors contributed to manuscript preparation and approved the submitted version.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.